Earthquake Early Warning Education (E3)


Earthquake Early Warning Education (E3) Project
Participant Recruitment

In preparation for the implementation of Natural Resource Canada’s earthquake early warning system, the Earthquake Early Warning Education (E3) Project survey, is being conducted by Dr. Glenn Dolphin and Dr. Shona van Zijll de Jong, Department of Geoscience, University of Calgary. This research is funded by Natural Resources Canada and is in collaboration with the United States Geological Survey and the Incorporated Research Institutes for Seismology. The University of Calgary Conjoint Faculties Research Ethics Board has approved this study (REB22-0966).

Purpose of Study: The purpose of this study is to explore how people understand different aspects of earthquakes (namely magnitude and intensity), and how people’s perceptions of earthquakes influence their decision-making process around early warnings.

Who Can Participate? If you are aged 18 or older, you are eligible to participate.

Procedure: To participate, you need to complete this online survey. Your participation in this online survey is completely voluntary. You may quit the survey at any time. Your responses will also be anonymous. No information you share electronically can be traced to you or the computer you used. Your participation in the survey indicates you have read this consent information and agreed to participate in this anonymous survey. Depending upon the depth of your responses, participation time may vary from 10 to 20 minutes.


Currently recruiting participants: Yes

Eligible gender: Male, Female, Transgender, Other

Eligible ages: 18 to 110

Accepts healthy participants: Yes

Inclusion criteria:

Anyone is over 18 is eligible (and encouraged) to participate.

Exclusion criteria:

Anyone over 18 is eligible (and encouraged) to participate.


This study is not currently accepting expressions of interest via the website. Please see contact information below.

Additional information

Contact information

Principal investigator:

Glenn Dolphin

Clinical trial: